-
公开(公告)号：EP4276166A1
公开(公告)日：2023-11-15
申请号：EP22736774.5
申请日：2022-01-06
摘要： Disclosed are cell culture vessels capable of preventing the deformation of the culture vessels in a manipulation of taking in/out a cell or replacing a culture medium and preventing over-time increase in the concentration of carbon dioxide or and temporal decrease of pH of the culture medium and over-time temporal decrease of pH of the culture medium in cell culture as advantageous effects, and further parallel filter connectors for configuring such cell culture vessels. The cell culture vessels have two types of filters in parallel so as to partition a gas phase inside the cell culture vessel and the outer air, and the parallel filter connectors for configuring the cell culture vessels have an opening to be connected to the body of the cell culture vessel, and two openings capable to be installed with each one of the two types of different filters.
-
公开(公告)号：EP4198129A1
公开(公告)日：2023-06-21
申请号：EP21861695.1
申请日：2021-08-27
摘要： The present invention relates to a mutant of human a-N-acetylglucosaminidase (hNAGLU), more specifically a hNAGLU mutant produced by adding a mutation to an amino acid sequence for hNAGLU such that an expression level of hNAGLU in a host cell in which a gene encoding hNAGLU is introduced can be increased compared with the case where a gene encoding wild-type hNAGLU is introduced. For example, the hNAGLU mutant has an amino acid sequence represented by SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 15, or SEQ ID NO: 19, or has an amino acid sequence introduced a mutation to the amino acid sequence of any one of the hNAGLU mutants.
-
公开(公告)号：EP4108676A1
公开(公告)日：2022-12-28
申请号：EP21756644.7
申请日：2021-02-22
发明人： TAKAHASHI, Kenichi , YODEN, Eiji , HASHIMOTO, Hidehiko , FUJIYAMA, Saki , OHUCHI, Masaki , NAKAMURA, Naoko , BASHIRUDDIN, Nasir Kato , SAWAI, Naoki , EHARA, Takeru , TAKUWA, Masatoshi , MASUYA, Keiichi , INABA, Shinnosuke
摘要： [Problem] To provide a peptide, etc., capable of passing through the blood-brain barrier (BBB) by binding to a human transferrin receptor (hTfR). [Solution] A peptide, etc., having the amino acid sequence shown in SEQ ID NO: 1 (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys) or an amino acid sequence having substitutions, deletions, additions, and/or insertions of 1 to 10 amino acid residues (inclusive) in the amino acid sequence shown in SEQ ID NO: 1.
-
公开(公告)号：EP4098267A1
公开(公告)日：2022-12-07
申请号：EP21748145.6
申请日：2021-01-29
发明人： IMAGAWA, Kiwamu , MINAMI, Kohtaro , MAEDA, Kenichi , HOSODA, Yuki , WATANABE, Shunsuke , SATO, Kazutoshi , HIGASHIGUCHI, Yasuna , KUSHIDA, Takashi , ISHIWARI, Ayumi , TSUSHIMA, Yu , MIYAUCHI, Yoshiteru
IPC分类号： A61K35/28 , A61K9/10 , A61K47/02 , A61K47/12 , A61K47/20 , A61K47/22 , A61K47/42 , A61P1/18 , A61P7/04 , A61P9/04 , A61P9/10 , A61P9/14 , A61P11/00 , A61P11/06 , A61P17/00 , A61P27/02 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/16
摘要： [Problem] To provide a pharmaceutical composition having a novel use comprising a dental pulp-derived multipotent stem cell preparation that can be administered to humans.
[Solution] A pharmaceutical composition comprising dental pulp-derived stem cells as an active ingredient for suppressing infiltration into a tissue of at lease neutrophils, monocytes, or lymphocytes.-
5.发明公开
公开(公告)号：EP3871748A1
公开(公告)日：2021-09-01
申请号：EP19876978.8
申请日：2019-10-21
摘要： A filtration filter is configured from a first weld frame, a second weld frame, and a filter sandwiched and welded between the first weld frame and the second weld frame. The first weld frame and the second weld frame are configured by a flexible film having a film thickness of at least 120 µm. The filter is configured by a substance having a higher melting point than the first weld frame and the second weld frame and having an opening area ratio of from 10% to 80%. The first weld frame is configured by a polymer that includes either a high density polyethylene having a melting point of from 120°C to 140°C, a linear low density polyethylene having a melting point of from 105°C to 125°C, or a mixture including at least one of the high density polyethylene or the linear low density polyethylene.
-
-
公开(公告)号：EP3348635A1
公开(公告)日：2018-07-18
申请号：EP16844430.5
申请日：2016-09-08
IPC分类号： C12N15/09 , A61K38/00 , A61P5/10 , A61P19/00 , A61P43/00 , C07K14/765 , C07K19/00 , C12N5/16
CPC分类号： C07K14/765 , A61K38/00 , A61P3/00 , A61P5/06 , A61P43/00 , C07K14/61 , C07K19/00 , C07K2319/00 , C12N5/16 , C12N15/09
摘要： Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.
-
公开(公告)号：EP2877575B1
公开(公告)日：2018-06-27
申请号：EP13822148.6
申请日：2013-07-24
发明人： ASANO, Masahiro , YAGI, Toshihiro , FUKUI, Tsuyoshi , KAWASAKI, Atsuko , HATANO, Yukichi , MIHARA, Kazutoshi , SUGIMURA, Atsushi
IPC分类号： C12N9/40
CPC分类号： C12N9/2465
摘要： Disclosed is a method for production of recombinant human alpha-galactosidase A (rh alpha-Gal A) in a large scale, with a high purity. The method comprises the steps of (a) culturing rh alpha-Gal A-producing mammalian cells in a serum-free medium, (b) collecting culture supernatant, (c) subjecting the culture supernatant to anion-exchange column chromatography, (d) to hydrophobic column chromatography, (e) to a column chromatography employing as solid phase a material having affinity for phosphate group, (f) to cation-exchange column chromatography, and (g) to gel filtration column chromatography, in the order.
-
9.发明公开
公开(公告)号：EP3315606A1
公开(公告)日：2018-05-02
申请号：EP16814464.0
申请日：2016-06-24
IPC分类号： C12N15/09 , A61K39/395 , A61K45/00 , A61P9/10 , A61P21/02 , A61P21/04 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P31/04 , A61P31/12 , A61P35/00 , C07K14/475 , C07K16/18 , C07K16/28 , C07K16/46 , C07K19/00
CPC分类号： C07K16/28 , A61K39/395 , A61K45/00 , A61K2039/505 , A61P25/00 , C07K14/475 , C07K14/505 , C07K14/7151 , C07K16/18 , C07K16/46 , C07K19/00 , C07K2317/24 , C07K2317/92 , C07K2319/30 , C12N5/10 , C12N9/10 , C12N9/14 , C12N9/16 , C12N9/24 , C12N9/2402 , C12N9/48 , C12N9/64 , C12N15/09 , C12N15/113 , C12Y301/02 , C12Y302/01076 , C12Y304/14009 , C12Y310/01001
摘要： Disclosed are a means to convert compounds having physiological or pharmacological activity and unable to pass through the blood-brain barrier into a form that allows them to pass through the blood-brain barrier, and compounds converted thereby. The means is an anti-human transferrin receptor antibody and the converted compounds are molecular conjugates between physiologically active protein or pharmacologically active low-molecular-weight compounds and an anti-human transferrin receptor antibody.
摘要翻译： 公开了一种将具有生理或药理活性并且不能通过血脑屏障的化合物转化为允许它们穿过血脑屏障的形式以及由此转化的化合物的手段。 该手段是抗人转铁蛋白受体抗体，并且转化的化合物是生理活性蛋白质或药理活性低分子量化合物与抗人转铁蛋白受体抗体之间的分子缀合物。
-
公开(公告)号：EP2668272B1
公开(公告)日：2017-10-25
申请号：EP12739815.4
申请日：2012-01-23
发明人： MIHARA, Kazutoshi , KAWASAKI, Atsuko , OOTSUKI, Kouta , HATANO, Yuukichi , KAMEI, Shoichiro , SUGIMURA, Atsushi
CPC分类号： C12N9/16 , C12Y301/06013
-
-
-
-
-
-
-
-
-
搜索结果
209 条记录 (耗时 0.031 秒)
